Macroscale delivery systems for molecular and cellular payloads
Source abstract
Abstract
Macroscale drug delivery (MDD) devices are engineered to exert spatiotemporal control over the presentation of a wide range of bioactive agents, including small molecules, proteins and cells. In contrast to systemically delivered drugs, MDD systems act as a depot of drug localized to the treatment site, which can increase drug effectiveness while reducing side effects and confer protection to labile drugs. In this Review, we highlight the key advantages of MDD systems, describe their mechanisms of spatiotemporal control and provide guidelines for the selection of carrier materials. We also discuss the combination of MDD technologies with classic medical devices to create multifunctional MDD devices that improve integration with host tissue, and the use of MDD technology in tissue-engineering strategies to direct cell behaviour. As our ever-expanding knowledge of human biology and disease provides new therapeutic targets that require precise control over their application, the importance of MDD devices in medicine is expected to increase.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · 3D Printing in Biomedical Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Dang, J. M. & Leong, K. W. Natural polymers for gene delivery and tissue engineering. Adv. Drug Deliv. Rev. 58, 487–499 (2006).10.1016/j.addr.2006.03.001 ↗
2. Folkman, J., Long, D. M. & Rosenbaum, R. Silicone rubber: A new diffusion property useful for general anesthesia. Science 154, 148–149 (1966).10.1126/science.154.3745.148 ↗
3. Hoffman, A. S. The origins and evolution of 'controlled' drug delivery systems. J. Control. Release 132, 153–163 (2008).10.1016/j.jconrel.2008.08.012 ↗
4. Langer, R. & Folkman, J. Polymers for the sustained release of proteins and other macromolecules. Nature 263, 797–800 (1976).10.1038/263797a0 ↗
5. Kanasty, R., Dorkin, R. J., Vegas, A. & Anderson, D. Delivery materials for siRNA therapeutics. Nature Mater. 12, 967–977 (2013).10.1038/nmat3765 ↗
6. Irvine, D. J., Swartz, M. A. & Szeto, G. L. Engineering synthetic vaccines using cues from natural immunity. Nature Mater. 12, 978–990 (2013).10.1038/nmat3775 ↗
7. Mura, S., Nicolas, J. & Couvreur, P. Stimuli-responsive nanocarriers for drug delivery. Nature Mater. 12, 991–1003 (2013).10.1038/nmat3776 ↗
8. Roseman, T. J. Release of steroids from a silicone polymer. J. Pharm. Sci. 61, 46–50 (1972).10.1002/jps.2600610106 ↗
9. Pitt, C. G., Gratzl, M. M., Jeffcoat, A. R., Zweidinger, R. & Schindler, A. Sustained drug delivery systems II: Factors affecting release rates from poly(ɛ-caprolactone) and related biodegradable polyesters. J. Pharm. Sci. 68, 1534–1538 (1979).10.1002/jps.2600681219 ↗
10. Langer, R. Polymeric delivery systems for controlled drug release. Chem. Eng. Comm. 6, 1–48 (1980).10.1080/00986448008912519 ↗
11. Augst, A., Kong, H. & Mooney, D. Alginate hydrogels as biomaterials. Macromol. Biosci. 6, 623–633 (2006).10.1002/mabi.200600069 ↗
12. Young, S., Wong, M., Tabata, Y. & Mikos, A. G. Gelatin as a delivery vehicle for the controlled release of bioactive molecules. J. Control. Release 109, 256–274 (2005).10.1016/j.jconrel.2005.09.023 ↗
13. Bhattarai, N., Gunn, J. & Zhang, M. Chitosan-based hydrogels for controlled, localized drug delivery. Adv. Drug Deliv. Rev. 62, 83–99 (2010).10.1016/j.addr.2009.07.019 ↗
14. Janmey, P. A., Winer, J. P. & Weisel, J. W. Fibrin gels and their clinical and bioengineering applications. J. R. Soc. Interface 6, 1–10 (2009).10.1098/rsif.2008.0327 ↗
15. Uhrich, K. E., Cannizzaro, S. M., Langer, R. S. & Shakesheff, K. M. Polymeric systems for controlled drug release. Chem. Rev. 99, 3181–3198 (1999).10.1021/cr940351u ↗
16. Tanaka, H., Matsumura, M. & Veliky, I. A. Diffusion characteristics of substrates in Ca-alginate gel beads. Biotechnol. Bioeng. 26, 53–58 (1984).10.1002/bit.260260111 ↗
17. Lin, C-C. & Metters, A. T. Hydrogels in controlled release formulations: network design and mathematical modeling. Adv. Drug Deliv. Rev. 58, 1379–1408 (2006).10.1016/j.addr.2006.09.004 ↗
18. Am Ende, M. T. & Peppas, N. A. Transport of ionizable drugs and proteins in crosslinked poly(acrylic acid) and poly(acrylic acid-co-2-hydroxyethyl methacrylate) hydrogels. I. Polymer characterization. J. Appl. Polym. Sci. 59, 673–685 (1996).10.1002/(SICI)1097-4628(19960124)59:4<673::AID-APP13>3.0.CO;2-R ↗
19. Am Ende, M. T. & Peppas, N. A. Transport of ionizable drugs and proteins in crosslinked poly(acrylic acid) and poly(acrylic acid-co-2-hydroxyethyl methacrylate) hydrogels. II. Diffusion and release studies. J. Control. Release 48, 47–56 (1997).10.1016/S0168-3659(97)00032-1 ↗
20. Silva, A. K. A., Richard, C., Bessodes, M., Scherman, D. & Merten, O-W. Growth factor delivery approaches in hydrogels. Biomacromolecules 10, 9–18 (2009).10.1021/bm801103c ↗
21. Peppas, N. A., Bures, P., Leobandung, W. & Ichikawa, H. Hydrogels in pharmaceutical formulations. Eur. J. Pharm. Biopharm. 50, 27–46 (2000).10.1016/S0939-6411(00)00090-4 ↗
22. Peppas, N. A., Hilt, J. Z., Khademhosseini, A. & Langer, R. Hydrogels in biology and medicine: From molecular principles to bionanotechnology. Adv. Mater. 18, 1345–1360 (2006).10.1002/adma.200501612 ↗
23. Lee, K., Silva, E. A. & Mooney, D. J. Growth factor delivery-based tissue engineering: General approaches and a review of recent developments. J. R. Soc. Interface 8, 153–170 (2011).10.1098/rsif.2010.0223 ↗
24. Gupta, P., Vermani, K. & Garg, S. Hydrogels: From controlled release to pH-responsive drug delivery. Drug Discov. Today 7, 569–579 (2002).10.1016/S1359-6446(02)02255-9 ↗
25. Hoare, T. R. & Kohane, D. S. Hydrogels in drug delivery: Progress and challenges. Polymer 49, 1993–2007 (2008).10.1016/j.polymer.2008.01.027 ↗
26. Lu, S. & Anseth, K. S. Photopolymerization of multilaminated poly(HEMA) hydrogels for controlled release. J. Control. Release 57, 291–300 (1999).10.1016/S0168-3659(98)00125-4 ↗
27. Galaev, I. Y. & Mattiasson, B. 'Smart' polymers and what they could do in biotechnology and medicine. Trends Biotechnol. 17, 335–340 (1999).10.1016/S0167-7799(99)01345-1 ↗
28. Miyata, T., Asami, N. & Uragami, T. A reversibly antigen-responsive hydrogel. Nature 399, 766–769 (1999).10.1038/21619 ↗
29. Zhang, J. & Peppas, N. A. Synthesis and characterization of pH- and temperature-sensitive poly(methacrylic acid)/poly(N-isopropylacrylamide) interpenetrating polymeric networks. Macromolecules 33, 102–107 (2000).10.1021/ma991398q ↗
30. Wang, N. X. & von Recum, H. A. Affinity-based drug delivery. Macromol. Biosci. 11, 321–332 (2011).10.1002/mabi.201000206 ↗
31. Borselli, C. et al. Functional muscle regeneration with combined delivery of angiogenesis and myogenesis factors. Proc. Natl Acad. Sci. USA 107, 3287–3292 (2010).10.1073/pnas.0903875106 ↗
32. Pike, D. B. et al. Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels containing VEGF and bFGF. Biomaterials 27, 5242–5251 (2006).10.1016/j.biomaterials.2006.05.018 ↗
33. Thatiparti, T. R., Shoffstall, A. J. & von Recum, H. A. Cyclodextrin-based device coatings for affinity-based release of antibiotics. Biomaterials 31, 2335–2347 (2010).10.1016/j.biomaterials.2009.11.087 ↗
34. Conrad, H. E. Heparin-Binding Proteins (Academic, 1997).
35. Silva, E. A. & Mooney, D. J. Effects of VEGF temporal and spatial presentation on angiogenesis. Biomaterials 31, 1235–1241 (2010).10.1016/j.biomaterials.2009.10.052 ↗
36. Freeman, I., Kedem, A. & Cohen, S. The effect of sulfation of alginate hydrogels on the specific binding and controlled release of heparin-binding proteins. Biomaterials 29, 3260–3268 (2008).10.1016/j.biomaterials.2008.04.025 ↗
37. Stockwell, A. F., Davis, S. S. & Walker, S. E. In vitro evaluation of alginate gel systems as sustained release drug delivery systems. J. Control. Release 3, 167–175 (1986).10.1016/0168-3659(86)90077-5 ↗
38. Vlatakis, G., Andersson, L. I., Müller, R. & Mosbach, K. Drug assay using antibody mimics made by molecular imprinting. Nature 361, 645–647 (1993).10.1038/361645a0 ↗
39. Hiratani, H., Mizutani, Y. & Alvarez-Lorenzo, C. Controlling drug release from imprinted hydrogels by modifying the characteristics of the imprinted cavities. Macromol. Biosci. 5, 728–733 (2005).10.1002/mabi.200500065 ↗
40. Alvarez-Lorenzo, C. & Concheiro, A. Molecularly imprinted polymers for drug delivery. J. Chromatogr. B 804, 231–245 (2004).10.1016/j.jchromb.2003.12.032 ↗
41. Rachkov, A. & Minoura, N. Towards molecularly imprinted polymers selective to peptides and proteins. The epitope approach. Biochim. Biophys. Acta 1544, 255–266 (2001).10.1016/S0167-4838(00)00226-0 ↗
42. Richardson, T. P., Peters, M. C., Ennett, A. B. & Mooney, D. J. Polymeric system for dual growth factor delivery. Nature Biotechnol. 19, 1029–1034 (2001).10.1038/nbt1101-1029 ↗
43. Ishihara, M. et al. Controlled release of fibroblast growth factors and heparin from photocrosslinked chitosan hydrogels and subsequent effect on in vivo vascularization. J. Biomed. Mater. Res. A 64, 551–559 (2003).10.1002/jbm.a.10427 ↗
44. Wood, K. C., Chuang, H. F., Batten, R. D., Lynn, D. M. & Hammond, P. T. Controlling interlayer diffusion to achieve sustained, multiagent delivery from layer-by-layer thin films. Proc. Natl Acad. Sci. USA 103, 10207–10212 (2006).10.1073/pnas.0602884103 ↗
45. Hammond, P. T. Form and function in multilayer assembly: New applications at the nanoscale. Adv. Mater. 16, 1271–1293 (2004).10.1002/adma.200400760 ↗
46. Macdonald, M. L. et al. Tissue integration of growth factor-eluting layer-by-layer polyelectrolyte multilayer coated implants. Biomaterials 32, 1446–1453 (2011).10.1016/j.biomaterials.2010.10.052 ↗
47. Leong, K. W., Brott, B. C. & Langer, R. Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation, and release characteristics. J. Biomed. Mater. Res. 19, 941–955 (1985).10.1002/jbm.820190806 ↗
48. Wood, K. C. et al. Electroactive controlled release thin films. Proc. Natl Acad. Sci. USA 105, 2280–2285 (2008).10.1073/pnas.0706994105 ↗
49. Kost, J., Leong, K. & Langer, R. Ultrasound-enhanced polymer degradation and release of incorporated substances. Proc. Natl Acad. Sci. USA 86, 7663–7666 (1989).10.1073/pnas.86.20.7663 ↗
50. Liu, T-Y., Hu, S-H., Liu, T-Y., Liu, D-M. & Chen, S-Y. Magnetic-sensitive behavior of intelligent ferrogels for controlled release of drug. Langmuir 22, 5974–5978 (2006).10.1021/la060371e ↗
51. Santini, J. T., Cima, M. J. & Langer, R. A controlled-release microchip. Nature 397, 335–338 (1999).10.1038/16898 ↗
52. Pitt, W. G., Husseini, G. A. & Staples, B. J. Ultrasonic drug delivery: A general review. Expert Opin. Drug Deliv. 1, 37–56 (2004).10.1517/17425247.1.1.37 ↗
53. Zhao, X. et al. Active scaffolds for on-demand drug and cell delivery. Proc. Natl Acad. Sci. USA 108, 67–72 (2011).10.1073/pnas.1007862108 ↗
54. Murdan, S. Electro-responsive drug delivery from hydrogels. J. Control. Release 92, 1–17 (2003).10.1016/S0168-3659(03)00303-1 ↗
55. Sawahata, K., Hara, M., Yasunaga, H. & Osada, Y. Electrically controlled drug delivery system using polyelectrolyte gels. J. Control. Release 14, 253–262 (1990).10.1016/0168-3659(90)90165-P ↗
56. Farra, R. et al. First-in-human testing of a wirelessly controlled drug delivery microchip. Sci. Transl. Med. 4, 122ra21 (2012).10.1126/scitranslmed.3003276 ↗
57. Lutolf, M. P. & Hubbell, J. A. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nature Biotechnol. 23, 47–55 (2005).10.1038/nbt1055 ↗
58. Kuhl, P. R. & Griffith-Cima, L. G. Tethered epidermal growth factor as a paradigm for growth factor–induced stimulation from the solid phase. Nature Med. 2, 1022–1027 (1996).10.1038/nm0996-1022 ↗
59. Mann, B. K., Schmedlen, R. H. & West, J. L. Tethered-TGF-β increases extracellular matrix production of vascular smooth muscle cells. Biomaterials 22, 439–444 (2001).10.1016/S0142-9612(00)00196-4 ↗
60. Liu, H-W., Chen, C-H., Tsai, C-L., Lin, I-H. & Hsiue, G-H. Heterobifunctional poly(ethylene glycol)-tethered bone morphogenetic protein-2-stimulated bone marrow mesenchymal stromal cell differentiation and osteogenesis. Tissue Eng. 13, 1113–1124 (2007).10.1089/ten.2006.0209 ↗
61. Schense, J. C. & Hubbell, J. A. Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa. Bioconjug. Chem. 10, 75–81 (1999).10.1021/bc9800769 ↗
62. Hubbell, J. A. Bioactive biomaterials. Curr. Opin. Biotechnol. 10, 123–129 (1999).10.1016/S0958-1669(99)80021-4 ↗
63. Ito, Y. Covalently immobilized biosignal molecule materials for tissue engineering. Soft Matter 4, 46–56 (2008).10.1039/B708359A ↗
64. Sakiyama-Elbert, S. E., Panitch, A. & Hubbell, J. A. Development of growth factor fusion proteins for cell-triggered drug delivery. FASEB J. 15, 1300–1302 (2001).10.1096/fj.00-0564fje ↗
65. Schmoekel, H. G. et al. Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices. Biotechnol. Bioeng. 89, 253–262 (2005).10.1002/bit.20168 ↗
66. BCC Research Advanced Drug Delivery Systems: Technologies and Global Markets (2011); http://www.bccresearch.com
67. Markets and Markets Global Biomaterial Market (2010–2015) (2011); http://www.marketsandmarkets.com
68. Centers for Disease Control and Prevention (CDC) Number of All-listed Procedures for Discharges from Short-Stay Hospitals, by Procedure Category and Sex: United States, 2010. (2011); available via http://go.nature.com/Xu3rNU
69. Moses, J. W. et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. New Engl. J. Med. 349, 1315–1323 (2003).10.1056/NEJMoa035071 ↗
70. Stone, G. W. et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. New Engl. J. Med. 350, 221–231 (2004).10.1056/NEJMoa032441 ↗
71. Hwang, C. W., Wu, D. & Edelman, E. R. Physiological transport forces govern drug distribution for stent-based delivery. Circulation 104, 600–605 (2001).10.1161/hc3101.092214 ↗
72. Burt, H. M. & Hunter, W. L. Drug-eluting stents: A multidisciplinary success story. Adv. Drug Deliv. Rev. 58, 350–357 (2006).10.1016/j.addr.2006.01.014 ↗
73. Stefanini, G. G. et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 378, 1940–1948 (2011).10.1016/S0140-6736(11)61672-3 ↗
74. Byrne, R. A. et al. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. J. Am. Coll. Cardiol. 58, 1325–1331 (2011).10.1016/j.jacc.2011.06.027 ↗
75. Joner, M. et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48, 193–202 (2006).10.1016/j.jacc.2006.03.042 ↗
76. Dudek, D. et al. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention 7, 1060–1061 (2012).10.4244/EIJV7I9A168 ↗
77. Wieneke, H. et al. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. Catheter Cardiovasc. Interv. 60, 399–407 (2003).10.1002/ccd.10664 ↗
78. Kollum, M. et al. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis. Catheter Cardiovasc. Interv. 64, 85–90 (2005).10.1002/ccd.20213 ↗
79. Tang, C. et al. The impact of vascular endothelial growth factor-transfected human endothelial cells on endothelialization and restenosis of stainless steel stents. J. Vasc. Surg. 53, 461–471 (2011).10.1016/j.jvs.2010.08.020 ↗
80. Boden, S. D., Zdeblick, T. A., Sandhu, H. S. & Heim, S. E. The use of rhBMP-2 in interbody fusion cages: Definitive evidence of osteoinduction in humans. A preliminary report. Spine 25, 376–381 (2000).10.1097/00007632-200002010-00020 ↗
81. Govender, S. et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: A prospective, controlled, randomized study of four hundred and fifty patients. J. Bone Joint Surg. Am. 84, 2123–2134 (2002).10.2106/00004623-200212000-00001 ↗
82. McKay, W. F., Peckham, S. M. & Badura, J. M. A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE® Bone Graft). Int. Orthop. 31, 729–734 (2007).10.1007/s00264-007-0418-6 ↗
83. White, A. P. et al. Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion. Int. Orthop. 31, 735–741 (2007).10.1007/s00264-007-0422-x ↗
84. Carragee, E. J., Hurwitz, E. L. & Weiner, B. K. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: Emerging safety concerns and lessons learned. Spine J. 11, 471–491 (2011).10.1016/j.spinee.2011.04.023 ↗
85. Simmons, C. A., Alsberg, E., Hsiong, S., Kim, W. J. & Mooney, D. J. Dual growth factor delivery and controlled scaffold degradation enhance in vivo bone formation by transplanted bone marrow stromal cells. Bone 35, 562–569 (2004).10.1016/j.bone.2004.02.027 ↗
86. Hosseinkhani, H., Hosseinkhani, M., Khademhosseini, A. & Kobayashi, H. Bone regeneration through controlled release of bone morphogenetic protein-2 from 3-D tissue engineered nano-scaffold. J. Control. Release 117, 380–386 (2007).10.1016/j.jconrel.2006.11.018 ↗
87. Yamamoto, M., Takahashi, Y. & Tabata, Y. Controlled release by biodegradable hydrogels enhances the ectopic bone formation of bone morphogenetic protein. Biomaterials 24, 4375–4383 (2003).10.1016/S0142-9612(03)00337-5 ↗
88. Turing, A. M. The chemical basis of morphogenesis. Phil. Trans. R. Soc. Lond. B 641, 33–72 (1952).
89. Yuen, W. W., Du, N. R., Chan, C. H., Silva, E. A. & Mooney, D. J. Mimicking nature by codelivery of stimulant and inhibitor to create temporally stable and spatially restricted angiogenic zones. Proc. Natl Acad. Sci. USA 107, 17933–17938 (2010).10.1073/pnas.1001192107 ↗
90. Bragdon, C. R., Jasty, M., Greene, M., Rubash, H. E. & Harris, W. H. Biologic fixation of total hip implants. Insights gained from a series of canine studies. J. Bone Joint Surg. Am. 86-A Suppl 2, 105–117 (2004).10.2106/00004623-200412002-00015 ↗
91. Simion, M. et al. Vertical ridge augmentation using an equine block infused with recombinant human platelet-derived growth factor-BB: A histologic study in a canine model. Int. J. Periodont. Restor. Dent. 29, 245–255 (2009).
92. Simion, M., Rocchietta, I., Kim, D., Nevins, M. & Fiorellini, J. Vertical ridge augmentation by means of deproteinized bovine bone block and recombinant human platelet-derived growth factor-BB: A histologic study in a dog model. Int. J. Periodont. Restor. Dent. 26, 415–423 (2006).
93. Jaklenec, A., Stamp, A., Deweerd, E., Sherwin, A. & Langer, R. Progress in the tissue engineering and stem cell industry: “Are we there yet?” Tissue Eng. B Rev. 18, 155–166 (2012).10.1089/ten.teb.2011.0553 ↗
94. Langer, R. & Vacanti, J. Tissue engineering. Science 260, 920–926 (1993).10.1126/science.8493529 ↗
95. Mooney, D. J. & Vandenburgh, H. Cell delivery mechanisms for tissue repair. Cell Stem Cell 2, 205–213 (2008).10.1016/j.stem.2008.02.005 ↗
96. Hofmann, M. et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 111, 2198–2202 (2005).10.1161/01.CIR.0000163546.27639.AA ↗
97. Toma, C. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105, 93–98 (2002).10.1161/hc0102.101442 ↗
98. Fisher, R. A. & Strom, S. C. Human hepatocyte transplantation: Worldwide results. Transplantation 82, 441–449 (2006).10.1097/01.tp.0000231689.44266.ac ↗
99. Kim, B. S., Baez, C. E. & Atala, A. Biomaterials for tissue engineering. World J. Urol. 18, 2–9 (2000).10.1007/s003450050002 ↗
100. Malafaya, P. B., Silva, G. A. & Reis, R. L. Natural-origin polymers as carriers and scaffolds for biomolecules and cell delivery in tissue engineering applications. Adv. Drug Deliv. Rev. 59, 207–233 (2007).10.1016/j.addr.2007.03.012 ↗